NASDAQ: CELU · Life Sciences · 5 alerts · CIK 1752828
Share price
$0.6191Close, Nov 16
Market cap
$20.1M
Shares outstanding
32.45MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Celularity Inc filings on SEC EDGAR ↗
Celularity Partnership with Vesalius Longevity Labs Inc.
Celularity entered into an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs to establish a U.S.-based manufacturing and supply platform for Peptual-branded peptide active pharmaceutical ingredients (APIs). Celularity will utilize its Florham Park, New Jersey facility to perform downstream purification, processing, and analytical testing of bulk peptide material under cGMP standards.
Celularity Inc. reported a significant decrease in cash and cash equivalents from $6.18 million at the end of 2025 to $586,000 as of June 30, 2026. The company's total assets declined to $96.2 million, while it continues to focus on cellular therapy development and commercializing its biomaterials products.
Celularity Inc. appointed Naveen Jain, founder and CEO of Viome Life Sciences, to its Board of Directors. Mr. Jain was designated for the role by investors from a recent September 2026 financing, and his appointment coincides with the resignation of director Diane Parks.
Celularity Inc. entered into a Securities Purchase Agreement to issue up to $25.0 million in senior secured convertible promissory notes and warrants across two tranches. The company completed an initial closing of approximately $11.01 million in principal amount, with the notes bearing 10% interest and maturing in 24 months.
Celularity Inc. has regained compliance with Nasdaq's minimum bid price and minimum market value of listed securities requirements. However, the company remains deficient regarding the timely filing of its periodic reports and is working to complete those filings to fully regain compliance.